Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Ryan Widau

TitlePostdoctoral Scholar
InstitutionUniversity of Chicago
DepartmentRadiation Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Touchefeu Y, Koh SJ, Stirnimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver Int. 2021 Jun 26. PMID: 34173317.
      View in: PubMed
    2. Kudo M, Ikeda M, Galle PR, Yamashita T, Finn RS, Liang K, Wang C, Sakaguchi S, Abada P, Widau RC, Zhu AX. Ramucirumab in patients with advanced hepatocellular carcinoma and elevated a-fetoprotein: Outcomes by treatment-emergent ascites. Hepatol Res. 2021 Jun; 51(6):715-721. PMID: 33743189.
      View in: PubMed
    3. Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 04; 124(8):1388-1397. PMID: 33531690.
      View in: PubMed
    4. Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int. 2021 03; 41(3):598-607. PMID: 33188713.
      View in: PubMed
    5. Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Rep. 2021 Apr; 3(2):100215. PMID: 33392490.
      View in: PubMed
    6. Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Drove Ubreva N, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int. 2020 08; 40(8):2008-2020. PMID: 32279446.
      View in: PubMed
    7. Meyer T, Finn R, Kudo M, Kang Y, Yen C, Galle P, Llovet J, Assenat E, Brandi G, Motomura K, Okusaka T, Hubner R, Karwal M, Baron A, Ikeda M, Liang K, Wang C, Widau R, Schelman W, Zhu A. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Ann Oncol. 2019 Jul; 30 Suppl 4:iv133. PMID: 32085038.
      View in: PubMed
    8. Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019 08; 20(8):1109-1123. PMID: 31301962.
      View in: PubMed
    9. Ranoa DRE, Widau RC, Mallon S, Parekh AD, Nicolae CM, Huang X, Bolt MJ, Arina A, Parry R, Kron SJ, Moldovan GL, Khodarev NN, Weichselbaum RR. STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability. Cancer Res. 2019 04 01; 79(7):1465-1479. PMID: 30482772.
      View in: PubMed
    10. Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist. 2018 12; 23(12):1407-e136. PMID: 29853658.
      View in: PubMed
    11. Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018 05; 19(3):213-220.e4. PMID: 29317191.
      View in: PubMed
    12. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017 Nov 18; 390(10109):2266-2277. PMID: 28916371.
      View in: PubMed
    13. Widau RC, Parekh AD, Ranck MC, Golden DW, Kumar KA, Sood RF, Pitroda SP, Liao Z, Huang X, Darga TE, Xu D, Huang L, Andrade J, Roizman B, Weichselbaum RR, Khodarev NN. RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E484-91. PMID: 24434553.
      View in: PubMed
    14. Spiotto MT, Pytynia M, Liu GF, Ranck MC, Widau R. Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers. J Oral Maxillofac Res. 2013 Apr 01; 4(1):e1. PMID: 24422024.
      View in: PubMed
    15. Widau RC, Zheng Y, Sung CY, Zelivianskaia A, Roach LE, Bachmeyer KM, Abramova T, Desgardin A, Rosner A, Cunningham JM, Skapek SX. p19Arf represses platelet-derived growth factor receptor ß by transcriptional and posttranscriptional mechanisms. Mol Cell Biol. 2012 Nov; 32(21):4270-82. PMID: 22907756.
      View in: PubMed
    16. Zhang L, Widau RC, Herring BP, Gallagher PJ. Delta-like 1-Lysine613 regulates notch signaling. Biochim Biophys Acta. 2011 Dec; 1813(12):2036-43. PMID: 21985982.
      View in: PubMed
    17. Widau RC, Jin Y, Dixon SA, Wadzinski BE, Gallagher PJ. Protein phosphatase 2A (PP2A) holoenzymes regulate death-associated protein kinase (DAPK) in ceramide-induced anoikis. J Biol Chem. 2010 Apr 30; 285(18):13827-38. PMID: 20220139.
      View in: PubMed
    Widau's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _